Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 19/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.51 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2297868 | 0.87 | MAP2K1 (0.77) | MAP2K1KCNH2MAP2K2CYP3A4CYP2C9 | |
| SCHEMBL2293662 | 0.82 | MAP2K1 (0.57) | MAP2K1KCNH2MAP2K2CYP3A4CYP2C9 | |
| SCHEMBL2294791 | 0.81 | MAP2K1 (0.63) | MAP2K1KCNH2MAP2K2BRAFMAPK1 | |
| SCHEMBL2295932 | 0.80 | MAP2K1 (0.55) | MAP2K1MAP2K2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL4860341 | 0.79 | MAP2K1 (0.58) | MAP2K1KCNH2MAP2K2BRAFMAPK1 | |
| SCHEMBL4858651 | 0.78 | MAP2K1 (0.67) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL4853511 | 0.78 | MAP2K1 (0.80) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL27496775 | 0.78 | MAP2K1 (0.62) | MAP2K1KCNH2MAP2K2BRAFMAPK1 | |
| SCHEMBL1580002 | 0.78 | MAP2K1 (1.00) | MAP2K1MAP2K2BRAFMAPK1MAP2K5 | |
| SCHEMBL1580444 | 0.78 | MAP2K1 (0.50) | MAP2K1KCNH2MAP2K2BRAFMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841462-B2 | Bicyclic heterocycles as MEK kinase inhibitors | GENENTECH, INC. | 2014-09-23 | — | — | US | disclosed |
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENETECH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENETECH, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2010003025-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | GENENTECH, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190257-A1 | BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS | MAP2K7, MAP3K1, MAP3K5 | MAP2K1 11/4885KCNH2 3333/4885MAP2K2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.